When treating hemorrhoids are next due regard to hygiene and avoiding or preventing constipation, the scleroseren as a surgical intervention into account.
Symptomatic treatment of hemorrhoids and their pre-and postoperative treatment, proctitis, anal eczema.
Scheriproct may cause the occurrence of hemorrhoids is not cured. The preparation is well suited as pre-surgical treatment of hemorrhoids or scleroseren postopératoire and for treatment.
Cinchocain hydrochlorid. 500 mg - prednisolone. caproas 190 mg - Octyldodecanol. - Ricin. ol. - Ricin. ol. hydrogenat. - Macrogol. ricinoleas 400 - Chypre. essent. (Derog. 42/471) ad 100 g.
Posology and method of use:
Scheriproct Prior to use, preferably after a bowel movement, the anal area thoroughly cleaned.
The duration of treatment with Scheriproct could be 1 to 2 weeks should not exceed.
In general 2 times a day, morning and evening, making the first treatment days even maximum 3 times. If the condition is improved, often enough one use per day.
A little ointment about the size of a pea with the finger near the anus, anus and on the ring which lowered the top of the finger resistance of the sphincter must be overcome.
When rectal ointment should be applied, the vocal tract attached to the tube and carefully screwed in the anus are placed. Then by slight pressure on the tube a small amount of ointment into the intestine.
In highly inflamed and painful process, therefore, it may also have guessed the internal application of the ointment with your finger to take effect. Any fat nodules should be covered and if possible with careful finger printed.
This is a medicine, no prolonged use without medical advice, keep away from children, read the leaflet carefully. Ask your doctor or pharmacist. In case of side effects, contact your doctor.
Hypersensitivity part of the preparation, in particular local anesthetics of the amide.
Luetic or tuberculous processes in the treatment area; viros (eg, vaccinia, varicella, genital herpes), patients younger than 16 years, existing skin atrophy.
In other bacterial infections in the treatment area is an additional specific antibacterial therapy.
A prolonged treatment with Scheriproct one should avoid (see 'Undesirable effects').
Fungal In an additional specific therapy.
Pregnancy and lactation:
Certain corticosteroids in topical application teratogenic in animal studies. Possible teratogenic effects of corticosteroids for topical use in pregnant women are no adequate and controlled studies are available. Therefore, topical corticosteroids during pregnancy should only be applied should be (but not in large quantities or over long time), when the expected benefits outweigh the potential risk to the fetus. Pregnancy during the first 3 months would on principle but no corticoïdhoudende medicines for local use should be used.
Prednisoloncaproaat goes on in the milk. At therapeutic doses is unlikely to adversely affect the infant. Yet during the lactation period may Scheriproct only for short periods and only at the recommended dose (small amounts) are applied.
Occasionally, a burning sensation after application performance in the anal area, in rare cases, allergic reactions and skin irritation.
With prolonged use (more than 4 weeks) of Scheriproct his huidatrofieën or local side effects such as rebound effects can not be excluded.
With prolonged use, possible systemic effects, such as cinchocaïne caused by effects on the cardiovascular or central nervous system, and by the corticoids induced inhibition of the hypothalamic-anterior pituitary-adrenocortical axis.
Corticoids can delay wound healing.
The ointment may leave grease stains on the clothes but easily care.
Given the low levels of active ingredients, route of administration is an overdose unlikely. Nevertheless, in high doses or prolonged use of equipment on large skin surfaces, the occurrence of overdose symptoms theoretically conceivable. Given the presence of corticoids would especially be a suppression of the hypothalamus - anterior pituitary-adrenocortical axis (measure: progressive discontinuation of treatment), with the usual symptoms of chronic overdose a hypercorticoïdisme, further, and dose-dependent as a sign of a cinchocaïne intoxication, heart provoked symptoms, which may include range from nausea, vomiting, tremor, cramps to respiratory paralysis, and cardiovascular effects such as bradycardia, hypotonia, arrhythmias and cardiac arrest, in symptomatic treatment (with cramps: administering diazepam), any intensive care (with respiratory arrest: assisted breathing) require.
active systemic plasma levels could occur, as with all corticoids, interactions with enzyme inducers such as phenytoin and phenobarbital conceivable . The side effects of non-steroidal antiflogisitica on the gastric mucosa could be enhanced and use of potassium elimination saluretics would be increased. Systemic plasma levels during active use Scheriproct are used properly, not to be expected.
|Type of product||Medicine|